Medicare Enrolled
Dr. Farah Quyyumi, M.D.
Hematology & Oncology · Cerritos, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Quyyumi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Quyyumi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Quyyumi
Dr. Farah Quyyumi is a hematology & oncology specialist in Cerritos, CA, with 13 years of NPI registration. Based on federal Medicare data, Dr. Quyyumi performed 3,002 Medicare services across 467 unique beneficiaries.
Between the years covered by Open Payments, Dr. Quyyumi received a total of $10,406 from 72 pharmaceutical and/or device companies across 443 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Quyyumi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 13 years in practice
▲ Top 38% volume in CA
$10,406 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,002
Medicare services
Top 38% in CA for hematology & oncology
467
Unique beneficiaries
$32
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~231 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 1,620 | $19 | $84 |
| Anti-nausea injection (ondansetron/Zofran) | 444 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
256 | $0 | $0 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
147 | $68 | $286 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
118 | $156 | $672 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
94 | $109 | $479 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
77 | $14 | $92 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
51 | $122 | $600 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
48 | $13 | $81 |
| New patient office visit, complex (60-74 min) | 47 | $189 | $821 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
30 | $59 | $269 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
28 | $111 | $474 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
25 | $61 | $295 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
17 | $149 | $628 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.5% high complexity
81.4% medium
15.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$10,406
Total received (2018-2024)
Avg $1,487/year across 7 years
Top 31% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
72
Companies
443
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,525 (91.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$881 (8.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$19
2023
$325
2022
$2,631
2021
$2,926
2020
$1,829
2019
$2,233
2018
$442
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ARRAY BIOPHARMA INC
$19
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$959
PFIZER INC.
$739
Takeda Pharmaceuticals U.S.A., Inc.
$640
E.R. Squibb & Sons, L.L.C.
$504
Incyte Corporation
$486
Amgen Inc.
$391
Athenex Pharmaceutical Division, LLC
$350
Janssen Biotech, Inc.
$317
Alexion Pharmaceuticals, Inc.
$315
Astellas Pharma US Inc
$295
Celgene Corporation
$276
Seagen Inc.
$253
GlaxoSmithKline, LLC.
$241
GENZYME CORPORATION
$235
Bayer HealthCare Pharmaceuticals Inc.
$221
Karyopharm Therapeutics Inc.
$217
EISAI INC.
$196
Regeneron Healthcare Solutions, Inc.
$196
Lilly USA, LLC
$181
Genentech USA, Inc.
$176
Rigel Pharmaceuticals, Inc.
$166
Gilead Sciences, Inc.
$154
Merck Sharp & Dohme Corporation
$151
Eisai Inc.
$149
AstraZeneca Pharmaceuticals LP
$141
Exelixis Inc.
$140
Kite Pharma, Inc.
$128
Taiho Oncology, Inc.
$122
TerSera Therapeutics LLC
$121
Boehringer Ingelheim Pharmaceuticals, Inc.
$112
Blueprint Medicines Corporation
$109
Puma Biotechnology, Inc.
$102
TOLMAR Pharmaceuticals, Inc.
$102
TESARO, Inc.
$95
Seattle Genetics, Inc.
$93
BeiGene USA, Inc.
$86
Pharmacyclics LLC, An AbbVie Company
$82
Pharmacyclics LLC, an AbbVie Company
$80
Ipsen Biopharmaceuticals, Inc
$72
Secura Bio, Inc.
$71
Dova Pharmaceuticals
$69
ARRAY BIOPHARMA INC
$64
Foundation Medicine, Inc.
$49
JAZZ PHARMACEUTICALS INC.
$47
Merck Sharp & Dohme LLC
$46
EMD Serono, Inc.
$44
Global Blood Therapeutics, Inc.
$39
Progenics Pharmaceuticals, Inc.
$38
Sirtex Medical Inc
$35
PharmaEssentia USA Corporation
$34
GE HealthCare
$31
Clovis Oncology, Inc.
$29
Daiichi Sankyo Inc.
$28
Dendreon Pharmaceuticals LLC
$28
Myovant Sciences Inc.
$27
AVEO Pharmaceuticals, Inc.
$27
SECURA BIO, INC.
$25
SANOFI-AVENTIS U.S. LLC
$25
Verastem, Inc.
$25
Jazz Pharmaceuticals Inc.
$24
Epizyme, Inc.,
$22
Array BioPharma Inc.
$22
Lexicon Pharmaceuticals, Inc.
$21
Emmaus Medical, Inc.
$20
Tolmar, Inc.
$19
MorphoSys, US Inc.
$19
Sun Pharmaceutical Industries Inc.
$17
EUSA Pharma (US) LLC
$16
Deciphera Pharmaceuticals Inc.
$16
Acrotech Biopharma LLC
$15
Sobi, Inc
$14
Tactile Systems Technology Inc
$11
Top 3 companies account for 22.5% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALUNBRIG · AYVAKIT · Alecensa · Andexxa · Avastin · BAVENCIO · BELEODAQ · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · Braftovi · CABLIVI · CALQUENCE · COPIKTRA · CYRAMZA · Cabometyx · Copiktra · DARZALEX · Doptelet · ELIGARD · ELITEK · EMPLICITI · ENHERTU · ERLEADA · Endari · FARYDAK · FLEXITOUCH · FOTIVDA · FOUNDATIONFOCUS · FOUNDATIONONE · Farydak · GAMIFANT · GAVRETO · GAZYVA · GILOTRIF · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · JAKAFI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MVASI · NERLYNX · NINLARO · Nerlynx · Nplate · Nubeqa · ONUREG · OPDIVO · ORGOVYX · OXBRYTA · PADCEV · PEMAZYRE · PIQRAY · PROMACTA · PROVENGE · PYLARIFY · Padcev · Phesgo · Pomalyst · QINLOCK · REBLOZYL · RETACRIT · RYDAPT · Revlimid · Rubraca · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SUTENT · Stivarga · Sylvant · TABRECTA · TAGRISSO · TALZENNA · TASIGNA · TAZVERIK · TIVDAK · TUKYSA · Tavalisse · Trodelvy · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VOTRIENT · VYXEOS · Vitrakvi · XOSPATA · XPOVIO · XTANDI · Xermelo · Xospata · Xtandi · YONSA · ZEJULA · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (92%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
383
Per 100K population
3.9
County median income
$87,760
Nearest hospital
COLLEGE HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Quyyumi is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Quyyumi experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Quyyumi performed 1,620 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Quyyumi receive payments from pharmaceutical companies?
Yes. Dr. Quyyumi received a total of $10,406 from 72 companies across 443 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Quyyumi's costs compare to other hematology & oncology specialists in Cerritos?
Dr. Quyyumi's average Medicare payment per service is $32. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Quyyumi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Cerritos
Browse hematology & oncology specialists in Cerritos ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology